neuroscience drug development

VANCOUVER, British Columbia & BOSTON — March 10, 2026 Global biotechnology company Xenon Pharmaceuticals Inc. has announced the pricing...

CAMBRIDGE, Massachusetts — QurAlis Corporation has announced topline Phase 1 proof-of-mechanism clinical data demonstrating clear target engagement in patients...